View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
  1. News
November 30, 2020

Biogen and Sage Therapeutics to co-develop depression and tremor therapies

Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.

Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

Under the deal, Sage will get $1.525bn in cash which includes an upfront payment of $875m and $650m as an equity investment.

On achieving certain development and commercial milestones in zuranolone and SAGE-324 programmes, Sage is eligible to get up to $1.6bn as potential milestone payments.

Zuranolone is a potential two-week, once-daily oral therapy being developed for treating major depressive disorder (MDD), postpartum depression (PPD) and other psychiatric disorders.

The treatment is currently in Phase III development as part of the LANDSCAPE and NEST clinical programmes.

A positive allosteric modulator of GABA receptors, SAGE-324 is under evaluation for essential tremor and other neurological conditions like epilepsy and PD as part of Phase II development.

Biogen CEO Michel Vounatsos said: “We are excited about the potential to bring together Biogen ’s leading capabilities in neuroscience with Sage’s deep expertise in psychiatry.”

The companies will share responsibility and costs for development and profits and losses for commercialisation in the US.

According to the deal, Biogen will have exclusive licence to develop and commercialise zuranolone and SAGE-324 outside of the US, excluding rights to zuranolone in Japan, Taiwan and South Korea.

Furthermore, Sage will receive tiered royalties from Biogen .

Sage Therapeutics chief operating officer Mike Cloonan said: “With the recent and pending data outputs for zuranolone and SAGE-324, the timing is right for a collaboration between two like-minded companies committed to patients and driven by a passion for neuroscience and brain health.”

The closing of the deal should take place by the end of January.

In August, Biogen signed a binding agreement with Denali Therapeutics to develop and commercialise therapeutics for Parkinson’s disease.

Related Companies

Free Report
img

2022: So far In Venture Capital

Global investment in 2022 has been majorly dominated by North America, Europe, and Asia Pacific, whereas the Middle East, and South and Central America have recorded low investments comparatively. In light of this, Europe and North America have been identified as the major destinations for Private Equity and Venture Capital (PE/VC) investments.   GlobalData’s whitepaper analyzes which sectors PE/VC firms have been investing in, looking at Technology, Media, and Telecom, with these sectors recording $356 billion and a deal volume of over 10,000 deals in 2022. Healthcare, Financial Services, Business & Consumer Services, and Construction sectors have also seen high investment activity by PE/VC firms, recording a deal value of over $70 billion each.   But what can this mean for you?   Understand how the Deals Database on GlobalData Explorer can be leveraged to:  
  • Track the Aggregate Investment Volumes in PE/VC-Stage firms across geographies and sectors, in addition to viewing the specific deals that drove these volumes
  • Identify the top investors already active in any sector-Geography combinations
  • Assess the Performance of Financial and Legal Advisors, supporting the Dealmaking in any segment of choice (Customizable League tables)
  • Understand what is driving the PE/VC fundraising (Deal Rationale)
  Consult our full report here and optimize your business strategy.
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology